To formulate recommendations based on evidence, a literature search was done of PubMed with the keyword “Waldenström” between Jan 1, 2010, and Feb 29, 2020, with no language restrictions. Abstract presentations from the annual meetings of the American Society of Hematology, the European Hematology Association, the American Society of Clinical Oncology, the European Society of Medical Oncology, the International Conference in Malignant Lymphoma, and the International Workshop for Waldenström
ReviewConsensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
Introduction
Waldenström macroglobulinaemia is characterised by the malignant accumulation of IgM-secreting lymphoplasmacytic lymphoma cells in the bone marrow and other organs.1 Since the initial development of treatment recommendations at the second International Workshop for Waldenström macroglobulinaemia (IWWM-2) in 2002,2 treatment options for patients with Waldenström macroglobulinaemia have evolved, and treatment recommendations have been updated at subsequent workshops.3, 4, 5, 6 As part of the IWWM-10 (New York, NY, USA, Oct 11–13, 2018), a consensus panel was established to update the treatment recommendations for Waldenström macroglobulinaemia on the basis of the latest data from clinical trials.
Participants of the IWWM-10 were selected as members of the consensus panel depending on their expertise on Waldenström macroglobulinaemia and their participation in the discussions. The initial live open discussion took place during the actual IWWM-10 meeting in October, 2018, in New York. Following this meeting, two separate teleconferences (June, 2019, and January, 2020) were undertaken to further discuss and refine recommendations until consensus was reached. All consensus panel members participated in the live meeting and teleconferences. No external or financial support was received for the elaboration of these recommendations.
Section snippets
Anti-CD20 monoclonal antibody monotherapy
The chimeric anti-CD20 monoclonal antibody rituximab is the most commonly used monotherapy for the treatment of Waldenström macroglobulinaemia in the USA.7 Rituximab monotherapy has been prospectively evaluated in several studies (table 1). Rituximab can induce IgM flares, which are rapid increases of serum IgM (≥25%) shortly after rituximab exposure and can occur in 50% of patients with Waldenström macroglobulinaemia who have rituximab monotherapy.12, 13 IgM flares occur more commonly with
Recent clinical trials
The consensus panel endorses enrolment of patients with symptomatic Waldenström macroglobulinaemia in ongoing clinical trials (appendix p 2).
Priorities in future clinical trials
Treatment options for patients with Waldenström macroglobulinaemia are increasing and more targeted therapies are being used in everyday practice and clinical trials. However, the use of currently available targeted therapies needs further optimisation. Waldenström macroglobulinaemia is a rare disease; therefore, it is important to prioritise studies that will drive the development of innovative, effective, and safer therapies. Large studies require international collaboration and partnerships
Search strategy and selection criteria
References (76)
- et al.
Treatment recommendations in Waldenström's macroglobulinaemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinaemia
Semin Oncol
(2003) - et al.
Update on treatment recommendations from the Third International Workshop on Waldenström's macroglobulinaemia
Blood
(2006) - et al.
Treatment recommendations for patients with Waldenström macroglobulinaemia (WM) and related disorders: IWWM-7 consensus
Blood
(2014) - et al.
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinaemia
Blood
(2016) - et al.
Extended rituximab therapy in Waldenstrom's macroglobulinaemia
Ann Oncol
(2005) - et al.
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study
Lancet Haematol
(2017) - et al.
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenström's macroglobulinaemia
Ann Oncol
(2004) - et al.
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review
Lancet Haematol
(2018) - et al.
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinaemia
Blood
(2009) - et al.
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Lancet
(2013)
Two years rituximab maintenance vs observation after first line treatment with bendamustine plus rituximab (B-R) in patients with Waldenström's macroglobulinaemia (MW): results of a prospective, randomised, multicentre phase 3 study (the StiL NHL7-2008 MAINTAIN trial)
Blood
Primary therapy of Waldenstrom macroglobulinaemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): longterm results of a phase 2 study of the European Myeloma Network (EMN)
Blood
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinaemia
Blood
Ixazomib, rituximab and dexamethasone (IRD) in patients with relapsed or progressive Waldenstrom's macroblobulinaemia: results of the prospective phase I/II HOVON 124/Ecwm-R2 Trial
Blood
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Lancet Oncol
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia(iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
Lancet Oncol
Acalabrutinib monotherapy in patients with Waldenström macroglobulinaemia: a single-arm, multicentre, phase 2 study
Lancet Haematol
MYD88 L265P in Waldenström macroglobulinaemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
Blood
Ibrutinib treatment in Waldenström's macroglobulinaemia: follow-up efficacy and safety from the iNNOVATETM study
Blood
Ibrutinib for the treatment of Bing-Neel syndrome: a multicentre study
Blood
Indications for haematopoietic stem cell transplantation in patients with Waldenstrom's macroglobulinaemia: a consensus project of the EBMT Lymphoma Working Party (LWP)/European Consortium for Waldenstrom's Macroglobulinaemia (ECWM)/International Waldenstrom's Macroglobulinaemia Foundation (IWMF)
Blood
Phase 2 study of tirabrutinib (ONO/GS-4059), a second-generation Bruton's tyrosine kinase inhibitor, monotherapy in patients with treatment-naive or relapsed/refractory Waldenström macroglobulinaemia
Blood
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism
Blood
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
Blood
Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinaemia
Blood
Long-term follow-up of idelalisib monotherapy in patients with double refractory marginal zone lymphoma or lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinaemia
Blood
Open label non-randomised phase II study exploring chemo-free treatment association with idelalisib + obinutuzumab in patients with relapsed/refractory (R/R) Waldenstrom's macroglobulinaemia (MW), a filo trial: results of the intermediary analysis of the induction phase
Blood
Lymphoplasmacytic lymphoma
Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinaemia
J Clin Oncol
Evolution of management and outcomes in Waldenström macroglobulinaemia: a population-based analysis
Oncologist
Multicenter phase 2 trial of rituximab for Waldenström macroglobulinaemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)
Leuk Lymphoma
Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinaemia
N Engl J Med
Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group Study
Cancer
Rituximab intolerance in patients with Waldenström macroglobulinaemia
Br J Haematol
Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature
Medicine (Baltimore)
Rituximab and subcutaneous 2-chloro-2-deoxyadenosine combination treatment for patients with Waldenström macroglobulinaemia: clinical and biologic results of a phase II multicenter study
J Clin Oncol
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
Leukemia
Primary treatment of Waldenström macroglobulinaemia with dexamethasone, rituximab, and cyclophosphamide
J Clin Oncol
Cited by (89)
Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia
2023, Hematology/Oncology Clinics of North AmericaManagement of Waldenström Macroglobulinemia in Limited-Resource Settings
2023, Hematology/Oncology Clinics of North AmericaThe Management of Relapsed or Refractory Waldenström's Macroglobulinemia
2023, Hematology/Oncology Clinics of North AmericaProteasome Inhibitor-Based Regimens in the Frontline Management of Waldenström Macroglobulinemia
2023, Hematology/Oncology Clinics of North America